Advanced Fibrosis Detection for MASLD in Primary Care

Summary

This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.

Eligibility

Patients

Inclusion Criteria:

* Patients with a diagnosis code for MASLD
* Type 2 diabetes mellitus will

Exclusion Criteria:

* All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.
* pregnant women.

Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices.

Inclusion criteria:

1\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study.

Exclusion criteria:

None

Conditions3

Locations1 site

Browse More Trials